SG11202006617RA - Combination therapies for the treatment of hepatocellular carcinoma - Google Patents
Combination therapies for the treatment of hepatocellular carcinomaInfo
- Publication number
- SG11202006617RA SG11202006617RA SG11202006617RA SG11202006617RA SG11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA SG 11202006617R A SG11202006617R A SG 11202006617RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- hepatocellular carcinoma
- combination therapies
- therapies
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615848P | 2018-01-10 | 2018-01-10 | |
| PCT/US2019/012886 WO2019139977A1 (en) | 2018-01-10 | 2019-01-09 | Combination therapies for the treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006617RA true SG11202006617RA (en) | 2020-08-28 |
Family
ID=65411938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006617RA SG11202006617RA (en) | 2018-01-10 | 2019-01-09 | Combination therapies for the treatment of hepatocellular carcinoma |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11833119B2 (en) |
| EP (1) | EP3737377A1 (en) |
| JP (2) | JP7352569B2 (en) |
| KR (1) | KR20200121302A (en) |
| CN (1) | CN111787922A (en) |
| AU (1) | AU2019206480A1 (en) |
| BR (1) | BR112020014112A2 (en) |
| CA (1) | CA3088292A1 (en) |
| IL (1) | IL275981A (en) |
| MA (1) | MA51570A (en) |
| MX (1) | MX2020007375A (en) |
| SG (1) | SG11202006617RA (en) |
| WO (1) | WO2019139977A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117479958A (en) * | 2022-05-30 | 2024-01-30 | 石药集团中奇制药技术（石家庄）有限公司 | Pharmaceutical combination and pharmaceutical composition for the treatment of cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60126997T2 (en) | 2000-10-20 | 2007-10-25 | Eisai R&D Management Co., Ltd. | NITROGEN-CONTAINING AROMATIC RING COMPOUNDS FOR THE TREATMENT OF TUMORARY DISEASES |
| RS54033B1 (en) | 2003-12-25 | 2015-10-30 | Eisai R&D Management Co. Ltd. | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| RU2448708C3 (en) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | ANTI-TUMOR MEANS AGAINST THYROID CANCER CANCER |
| JP5638244B2 (en) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Combination of angiogenesis inhibitors and antitumor platinum complexes |
| US20140378422A1 (en) | 2012-01-31 | 2014-12-25 | Novartis Ag | Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer |
| KR102265952B1 (en) | 2013-06-26 | 2021-06-16 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| CN105899490B (en) * | 2013-10-18 | 2019-07-23 | 卫材R&D管理有限公司 | Pyrimidine FGFR4 inhibitor |
| WO2015144808A1 (en) * | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
| US20160089365A1 (en) * | 2014-09-25 | 2016-03-31 | Eisai R&D Management Co., Ltd. | Immunostimulatory compound |
| US10562888B2 (en) | 2015-04-14 | 2020-02-18 | Eisai R&D Management Co., Ltd. | Crystalline FGFR4 inhibitor compound and uses thereof |
| CN107304188A (en) * | 2016-04-20 | 2017-10-31 | 成都融科博海科技有限公司 | A kind of deuterated Kinase Selectivity inhibitor and its application |
| WO2017196854A1 (en) * | 2016-05-10 | 2017-11-16 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
-
2019
- 2019-01-09 US US16/961,292 patent/US11833119B2/en active Active
- 2019-01-09 JP JP2020558858A patent/JP7352569B2/en active Active
- 2019-01-09 BR BR112020014112-7A patent/BR112020014112A2/en unknown
- 2019-01-09 SG SG11202006617RA patent/SG11202006617RA/en unknown
- 2019-01-09 EP EP19705261.6A patent/EP3737377A1/en active Pending
- 2019-01-09 WO PCT/US2019/012886 patent/WO2019139977A1/en unknown
- 2019-01-09 CA CA3088292A patent/CA3088292A1/en active Pending
- 2019-01-09 AU AU2019206480A patent/AU2019206480A1/en active Pending
- 2019-01-09 KR KR1020207022999A patent/KR20200121302A/en unknown
- 2019-01-09 MX MX2020007375A patent/MX2020007375A/en unknown
- 2019-01-09 MA MA051570A patent/MA51570A/en unknown
- 2019-01-09 CN CN201980015321.XA patent/CN111787922A/en active Pending
-
2020
- 2020-07-12 IL IL275981A patent/IL275981A/en unknown
-
2023
- 2023-09-15 JP JP2023149903A patent/JP2023175825A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019206480A1 (en) | 2020-08-27 |
| WO2019139977A1 (en) | 2019-07-18 |
| RU2020126673A3 (en) | 2022-04-19 |
| IL275981A (en) | 2020-08-31 |
| RU2020126673A (en) | 2022-02-10 |
| CA3088292A1 (en) | 2019-07-18 |
| JP7352569B2 (en) | 2023-09-28 |
| MA51570A (en) | 2020-11-18 |
| EP3737377A1 (en) | 2020-11-18 |
| US11833119B2 (en) | 2023-12-05 |
| JP2023175825A (en) | 2023-12-12 |
| KR20200121302A (en) | 2020-10-23 |
| JP2021512140A (en) | 2021-05-13 |
| MX2020007375A (en) | 2020-11-09 |
| US20200360371A1 (en) | 2020-11-19 |
| BR112020014112A2 (en) | 2020-12-01 |
| CN111787922A (en) | 2020-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL249065A0 (en) | Combination therapies for the treatment of cancer | |
| PL3600281T3 (en) | Combination therapy for the treatment or prevention of tumours | |
| HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
| IL276398A (en) | Combination therapy for the treatment of mastocytosis | |
| HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| IL264950A (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| IL280337A (en) | Lag-3 combination therapy for the treatment of cancer | |
| IL283948A (en) | Methods for the treatment of depression | |
| IL269357A (en) | Combination therapies for the treatment of breast cancer | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| IL276935A (en) | Therapeutic agent for hepatocellular carcinoma | |
| IL264589A (en) | Combination therapy for the treatment of pancreatic cancer | |
| IL284162A (en) | Combination therapy for the treatment of cancer | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| IL281997A (en) | Combination therapy for the treatment of uveal melanoma | |
| SG11202006617RA (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| IL280066A (en) | Injection techniques for the treatment of cellulite | |
| IL266726A (en) | Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions | |
| EP3624800A4 (en) | Treatment of hepatocellular carcinoma | |
| IL253642A0 (en) | Combination therapy for the treatment of cancer |